US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Champion Industries, Inc.

0.0200

0.0000

Volume:- -

Turnover:- -

Market Cap:1.12K

PE:0.00

High:0.0200

Open:0.0200

Low:0.0200

Close:0.0200

52wk High:0.0200

52wk Low:0.0001

Shares:55.86K

Float Shares:- -

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.0334

EPS(LYR):-23.0334

ROE:-49.45%

ROA:-1.87%

PB:0.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Incyte announces CHMP opinion recommending approval of Minjuvi combination

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Anavex Faces CHMP Setback for Alzheimer’s Drug

Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

Press Release: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs

Simply Wall St.

GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?

Simply Wall St.

Why Is Protalix BioTherapeutics Stock Falling On Friday?

Benzinga_recent_news

Agios Gets CHMP Backing of Pyrukynd in Thalassemia

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Novartis Scemblix receives positive CHMP opinion for Scemblix

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.02,"timestamp":1774641600000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"03-27 16:00:00 EDT Delay","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0.014044951710647027},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":0.014044951710647027,"shares":55857,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.02,"institutionHeld":0,"latestPrice":0.02,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.02,"prevYearClose":0.02,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.02,"twentyDayClose":0.02,"sixtyDayClose":0.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584642687","title":"High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642687?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/17/3188941/0/en/High-Dose-Regimen-of-Nusinersen-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Spinal-Muscular-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1165135440.EUR","LU1815336091.USD","BK4087","LU1169590202.USD","BK4081","LU2308191902.HKD","LU1543694498.USD","LU1596574779.USD","LU2229751404.USD","LU2413665964.HKD","LU2089279066.USD","LU2125910179.SGD","LU1620156130.USD","LU1620156213.USD","WMS","LU2125910336.SGD","IE00BN0W2T93.GBP","LU0757428866.USD","CHMP","LU1721427968.SGD","LU0054578231.USD","LU1923621640.USD","LU2413666004.HKD","BK4217","BK4086","LU0106261612.USD","LU1169589451.USD","IE00BN0W2V16.EUR","LU0728928796.USD","SMA","IE00BN0W2W23.USD","EMA","LU0012050646.USD"],"gpt_icon":0},{"id":"2584642833","title":"Incyte announces CHMP opinion recommending approval of Minjuvi combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642833","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642833?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:45","pubTimestamp":1763376314,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued an opinion recommending...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CHMP","BK4532","BK4585","INCY","BK4550","BK4139","BK4087"],"gpt_icon":0},{"id":"2583682450","title":"Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682450","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682450?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154300,"startTime":"0","endTime":"0","summary":"– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/14/3188609/0/en/Verrica-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BCC","BK4080","BK4081","BK4567","BK4087","CHMP","EMA","BK4231","SITC"],"gpt_icon":0},{"id":"2583506963","title":"Anavex Faces CHMP Setback for Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506963","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506963?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:58","pubTimestamp":1763125081,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, Anavex Life Sciences announced that the Committee for Medicinal Produc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2583506953","title":"Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506953","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506953?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:46","pubTimestamp":1763124391,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the European Medicines ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IONS","CHMP","BK4087"],"gpt_icon":0},{"id":"2583566564","title":"Press Release: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566564","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583566564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:50","pubTimestamp":1763034600,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:00 a.m. EST. CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.\"We are pleased to report total revenues of $43.6 million for the first nine months of 2025, an increase of 24%, compared to the same period in 2024. Our total revenues for the third quarter were $17.9 million which reflects a decrease of 1%, compared to revenues for the same period of 2024,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"We recognize revenues from sales of our products to Chiesi, Pfizer, and Fiocruz in Brazil, and their purchases vary from quarter to quarter as they control their ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","LU1023059063.AUD","LU0058720904.USD","IE000M9KFDE8.USD","LU0306806265.USD","BK4599","R","SG9999011175.SGD","LU1894683348.USD","SGXZ57979304.SGD","PLX","IE0002270589.USD","LU1894683264.USD","BK4581","LU0321505868.SGD","BK4139","CHMP","BK4592","BK4007","LU0225771236.USD","SG9999013999.USD","SG9999002224.SGD","SG9999002232.USD","LU1057294990.SGD","BK4081","BK4534","SG9999003800.SGD","LU0456855351.SGD","LU0306807586.USD","SG9999001176.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU0321505439.SGD","BK4568","LU0122379950.USD","LU0985481810.HKD","LU0234572021.USD","LU0170899867.USD","LU0868494617.USD","BK4533","IE00BBT3K403.USD","IE00B19Z3B42.SGD","SG9999001176.SGD","LU1883839398.USD","BK4022","BK4585","EMA","LU0225284248.USD"],"gpt_icon":1},{"id":"1189004134","title":"Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1189004134","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189004134?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:20","pubTimestamp":1763025640,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals (603087.SH) announced that the company and its wholly-owned European subsidiary, Gan&Lee Pharmaceuticals Europe GmbH, recently received notification from the European...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","BK4585","BK4087","BK0239","MAA","CHMP","FESXmain","BK4588","603087","FSXEmain"],"gpt_icon":0},{"id":"2583007873","title":"Ascendis Pharma Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583007873","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583007873?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":"– Q3 2025 revenue of 143.1 million for YORVIPATH and 50.7 million for SKYTROFA – Q3 2025 operating profit of 11.0 million – TransCon CNP (navepegritide) under FDA Priority Review for the treatment of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186726/0/en/Ascendis-Pharma-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","OS","BK4588","CHMP","BK4087","BK4590","BK4007","SGA","MAA","BK4581","PROC","BK4097","BK4215","BK4144","BK4585","ET","BK4125"],"gpt_icon":0},{"id":"2581726270","title":"Ocugen Provides Business Update with Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581726270","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581726270?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:30","pubTimestamp":1762342200,"startTime":"0","endTime":"0","summary":"Conference Call and Webcast Today at 8:30 a.m. ETPhase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181230/0/en/Ocugen-Provides-Business-Update-with-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","OCGN","BK4139","MAA","CHMP","BK4585","BK4087","EMA","BK4568","BK4215","BK4588","BK4563"],"gpt_icon":0},{"id":"2579170781","title":"Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:05","pubTimestamp":1761822300,"startTime":"0","endTime":"0","summary":"Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI (pegcetacoplan) in the first two months since launch in C3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009356076.USD","IE0004445239.USD","LU0823434583.USD","BK4534","BK4585","BK4573","BK4141","LU2250418816.HKD","BK4512","LU1861558580.USD","LU0979878070.USD","LU0823434740.USD","BK4532","LU1951198990.SGD","LU1951200564.SGD","LU2098885051.SGD","BK4087","LU1852331112.SGD","LU0823421333.USD","LU0390134368.USD","LU1064131342.USD","BK4543","LU1880398471.USD","LU1803068979.SGD","BK4575","CHMP","LU2054465674.USD","LU0109392836.USD","EMA","LU0082616367.USD","LU1242518857.USD","LU2360106780.USD","LU1316542783.SGD","LU2458330169.SGD","LU0823421416.USD","LU1880398554.USD","LU1303367103.USD","LU1988902786.USD","LU1242518931.SGD","LU0719512351.SGD","BK4566","LU0127658192.USD","FSGS","BK4529","LU0056508442.USD","LU0889565833.HKD","LU0642271901.SGD","IE00B5949003.HKD","BK4554"],"gpt_icon":1},{"id":"2579114441","title":"Agios Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579114441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579114441?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:30","pubTimestamp":1761820200,"startTime":"0","endTime":"0","summary":"$12.9 million in third quarter PYRUKYND (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177175/31990/en/Agios-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4087","BK4081","CHMP","GCC"],"gpt_icon":0},{"id":"2578630717","title":"CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs","url":"https://stock-news.laohu8.com/highlight/detail?id=2578630717","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578630717?lang=en_us&edition=fundamental","pubTime":"2025-10-26 17:25","pubTimestamp":1761470729,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) is gaining attention after two key developments: a positive opinion from Europe’s drug regulator for sugemalimab in lung cancer, and fresh data on its early-stage immunotherapy candidates. Investors are watching closely.\nSee our latest analysis for CStone Pharmaceuticals.\nThe recent surge in CStone Pharmaceuticals’ share price, up nearly 158% year-to-date, reflects growing investor confidence on the back of regulatory wins and progress with its immunotherapy...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","CHMP","BK4087","LARK","BK1574","02616","BK1161","DCF"],"gpt_icon":0},{"id":"2577405845","title":"GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2577405845","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577405845?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:23","pubTimestamp":1761027806,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Hu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","BK4007","GSK","CHMP","GSK.UK","BK4532","BK4585","BK4588","LU1829250122.USD"],"gpt_icon":0},{"id":"2577895071","title":"Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577895071","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577895071?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:45","pubTimestamp":1760993112,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (VRCA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided feed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRCA","MAA","BK4087","CHMP","BK4215","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2577489352","title":"Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489352","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489352?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:05","pubTimestamp":1760990700,"startTime":"0","endTime":"0","summary":"– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169756/0/en/Verrica-Pharmaceuticals-Receives-Positive-Feedback-from-the-European-Medicines-Agency-EMA-Supporting-a-Clear-Regulatory-Path-Forward-to-File-for-Approval-of-YCANTH-in-the-European-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4145","BK4202","MAA","EMA","BK4585","BK4081","MDCO","BK4588","FORD","CHMP","BK4215"],"gpt_icon":0},{"id":"2577866044","title":"How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577866044","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577866044?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:16","pubTimestamp":1760966206,"startTime":"0","endTime":"0","summary":"Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding Elfabrio’s proposed less-frequent dosing regimen for Fabry disease, as the data was considered insufficient to demonstrate similar efficacy to the currently approved schedule.\nThis regulatory decision highlights ongoing challenges in achieving flexibility for rare disease treatments, with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4081","BK4087","PLX","CHMP","BK4139","EMA"],"gpt_icon":0},{"id":"2576505793","title":"Why Is Protalix BioTherapeutics Stock Falling On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505793","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505793?lang=en_us&edition=fundamental","pubTime":"2025-10-17 23:23","pubTimestamp":1760714580,"startTime":"0","endTime":"0","summary":"EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/17/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/17/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48278076/why-is-protalix-biotherapeutics-stock-falling-on-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48278076/why-is-protalix-biotherapeutics-stock-falling-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CHMP","PLX","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","QURE","EMA","BK4081","BK4139","BK4087"],"gpt_icon":0},{"id":"2576978030","title":"Agios Gets CHMP Backing of Pyrukynd in Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2576978030","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576978030?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:36","pubTimestamp":1760704560,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia.Agios on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers Pyrukynd in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected by early next year, Agios said.The U.S. Food and Drug Administration is currently reviewing Pyrukynd in thalassemia, with a target action date of Dec. 7. The drug is already approved in the U.S. for the treatment of hemolytic anemia in adults with pyruvate-kinase, or PK, deficiency and in Europe for PK deficiency in adults.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4139","CHMP","AGIO"],"gpt_icon":0},{"id":"2576059714","title":"Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059714","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576059714?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168588/31990/en/Agios-PYRUKYND-mitapivat-Receives-Positive-CHMP-Opinion-for-Adults-with-Thalassemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","LU2065731478.USD","EMA","PK","BK4218","IE00BLDYK493.USD","RBC","BK4081","BK4181","BK4161","CHMP","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2576031359","title":"Novartis Scemblix receives positive CHMP opinion for Scemblix","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031359","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576031359?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:55","pubTimestamp":1760698518,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0211331839.USD","BK4532","IE00B2B36J28.USD","BK4007","IE0009355771.USD","LU0208291251.USD","BK4585","IE00BJJMRZ35.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","BK4588","IE00B4R5TH58.HKD","IE0002141913.USD","BK4578","NVS"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}